Luis Felipe Leite da Silva
Luis Felipe Leite da Silva/LinkedIn

Luis Felipe Leite da Silva: The Current Evidence on CDK4/6 Inhibitors Beyond Progression in Breast Cancer Treatment

Luis Felipe Leite da Silva, Teaching assistant at Meta-Analysis Academy, shared a post on LinkedIn:

“In this ESMO Open paper, we synthesize the current evidence on CDK4/6 inhibitors beyond progression in breast cancer treatment. This is a rapidly evolving field that is increasingly moving toward molecularly guided therapy.

For more mechanistic insights on this topic, check here.

This was a true collaborative effort, and I would like to thank Andreia Melo, who has been kindly mentoring me, as well as Paolo Tarantino, Jesse Lopes da Silva, Mariana Noronha, and all the team. A special thanks to Felipe Batalini, MD for his invaluable guidance.”

Title: Cyclin-dependent kinase 4/6 inhibitors beyond progression in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis (REIGNITE study)

Authors: L.F.C. de Almeida, L.F. Leite, V.O.C. Filho, M.M. Noronha, A.P. Cappellaro, M. Gouveia, J.L. da Silva, B. Ernst, A.C. de Melo, P. Tarantino, F. Batalini

Read the Full Article.

Luis Felipe Leite da Silva

More posts featuring Luis Felipe Leite da Silva.